Prospect of targeting lysine methyltransferase NSD3 for tumor therapy

Area of Science:

• Epigenetics
• Cancer Biology
• Molecular Oncology

Background:

• Nuclear receptor binding SET domain protein 3 (NSD3) is increasingly recognized as a significant factor in oncogenesis.
• NSD3 alterations (amplification, overexpression, mutation) are observed across various tumor types.
• NSD3 plays a crucial role in regulating fundamental cellular processes including the cell cycle, apoptosis, DNA repair, and epithelial-mesenchymal transition (EMT).

Purpose of the Study:

• To provide a comprehensive review of NSD3's structure and biological functions.
• To highlight NSD3's role in promoting cancer development and progression.
• To discuss the therapeutic potential of targeting NSD3, including inhibitors and degraders.

Main Methods:

• Literature review and synthesis of existing research on NSD3.
• Analysis of NSD3's involvement in key cancer-related pathways.
• Review of current strategies for NSD3 inhibition and degradation.

Main Results:

• NSD3 is implicated in promoting tumor development through its regulatory functions.
• Targeting NSD3 (via inhibition, silencing, or knockdown) presents a promising avenue for cancer therapy.
• The development of NSD3-specific inhibitors and degraders is an active area of research.

Conclusions:

• NSD3 is a critical epigenetic regulator with significant oncogenic activity.
• Targeting NSD3 offers a promising therapeutic strategy for various cancers.
• Further development of NSD3-specific agents is warranted for effective cancer treatment.